Remove 2028 Remove Food and Drug Administration Remove Networking Remove Safety
article thumbnail

Key developments: mRNA vaccines and therapeutics

European Pharmaceutical Review

A key benefit of mRNA therapeutics is that manufacturing time is fast compared to antibodies or protein-based drugs. Robust analytical methods are needed to establish safety, potency, and purity of mRNA therapeutics in large-scale manufacturing. billion during 2028, GlobalData forecasted in its report.